Video: Stem cell models of Alzheimer’s disease

The panelists discuss what value, if any, there is in using stem cell (ES/iPS-derived) models of AD; how are they best employed and what caveats do researchers face when using these systems?

Like Comment

Tim Spencer

Senior Editor, Nature Neuroscience

Tim Spencer received his PhD from the City University of New York, where he studied the signaling mechanisms which underlie the promotion of axonal growth and regeneration following injury in the laboratory of Marie Filbin. He then moved to the laboratory of Chris Henderson at Columbia University, where he examined molecular markers of postnatal motor neuron maturation and elements of neurodegenerative diseases such as ALS and SMA. His research interests include neuronal development and maturation, axonal guidance and models of neuronal disease and dysfunction. Tim joined the editorial team of Nature Neuroscience in March of 2011, where he handles many of the manuscripts on neural development and neurogenesis, neurodegeneration, neuroinflammation and neuroimmune interactions, myelination/remyelination, molecular and cellular pathways, and "brain cancer" (glioblastoma, etc.).


Go to the profile of Sandrine Willaime-Morawek
over 6 years ago
I agree with the very interesting points raised in this video. Some of these and other points about the usefeulness and limitations of usign iPSC to model AD are detailed in our latest review: The use of human neurons for novel drug discovery in dementia research